Department of Surgery and Cancer, Imperial College London & Imperial Vascular Unit, Imperial College Healthcare NHS Trust, London W6 8RF, UK.
Health Services Research Unit, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, UK.
BMJ. 2020 May 13;369:m1309. doi: 10.1136/bmj.m1309.
To investigate whether the use of graduated compression stockings (GCS) offers any adjuvant benefit when pharmaco-thromboprophylaxis is used for venous thromboembolism prophylaxis in patients undergoing elective surgery.
Open, multicentre, randomised, controlled, non-inferiority trial.
Seven National Health Service tertiary hospitals in the United Kingdom.
1905 elective surgical inpatients (≥18 years) assessed as being at moderate or high risk of venous thromboembolism were eligible and consented to participate.
Participants were randomly assigned (1:1) to receive low molecular weight heparin (LMWH) pharmaco-thromboprophylaxis alone or LMWH pharmaco-thromboprophylaxis and GCS.
The primary outcome was imaging confirmed lower limb deep vein thrombosis with or without symptoms, or pulmonary embolism with symptoms within 90 days of surgery. Secondary outcome measures were quality of life, compliance with stockings and LMWH, lower limb complications related to GCS, bleeding complications, adverse reactions to LMWH, and all cause mortality.
Between May 2016 and January 2019, 1905 participants were randomised. 1858 were included in the intention to treat analysis (17 were identified as ineligible after randomisation and 30 did not undergo surgery). A primary outcome event occurred in 16 of 937 (1.7%) patients in the LMWH alone group compared with 13 of 921 (1.4%) in the LMWH and GCS group. The risk difference between the two groups was 0.30% (95% confidence interval -0.65% to 1.26%). Because the 95% confidence interval did not cross the non-inferiority margin of 3.5% (P<0.001 for non-inferiority), LMWH alone was confirmed to be non-inferior.
For patients who have elective surgery and are at moderate or high risk of venous thromboembolism, administration of pharmaco-thromboprophylaxis alone is non-inferior to a combination of pharmaco-thromboprophylaxis and GCS. These findings indicate that GCS might be unnecessary in most patients undergoing elective surgery.
ISRCTN13911492.
研究在择期手术患者中使用药物血栓预防时,使用分级加压弹力袜(GCS)是否能提供辅助获益。
开放、多中心、随机、对照、非劣效性试验。
英国 7 家国民保健服务三级医院。
1905 名接受择期手术的住院患者(≥18 岁),评估为中危或高危静脉血栓栓塞,符合条件并同意参与。
参与者以 1:1 的比例随机分配(1:1)接受低分子肝素(LMWH)药物血栓预防单独治疗或 LMWH 药物血栓预防联合 GCS。
主要结局是手术 90 天内影像学证实的下肢深静脉血栓形成伴或不伴症状,或有症状的肺栓塞。次要结局是生活质量、GCS 和 LMWH 的依从性、与 GCS 相关的下肢并发症、出血并发症、LMWH 的不良反应和全因死亡率。
2016 年 5 月至 2019 年 1 月期间,共纳入 1905 名参与者进行随机分组。1858 名参与者进行意向治疗分析(17 名在随机分组后被确定为不合格,30 名未进行手术)。LMWH 单独组 937 名患者中有 16 例(1.7%)发生主要结局事件,LMWH 和 GCS 组 921 名患者中有 13 例(1.4%)。两组间的风险差异为 0.30%(95%置信区间-0.65%至 1.26%)。由于 95%置信区间未穿过 3.5%的非劣效性边界(P<0.001 表示非劣效性),因此证实 LMWH 单独治疗不劣于联合治疗。
对于接受择期手术且静脉血栓栓塞风险为中高危的患者,单独使用药物血栓预防治疗不劣于药物血栓预防联合 GCS。这些发现表明,在大多数接受择期手术的患者中,GCS 可能不是必需的。
ISRCTN8500610。